Kayothera

Kayothera, founded in 2019, is a pioneering biotechnology company headquartered in the United States. Their slogan, "Drugging the Undruggable," encapsulates their mission to develop inhibitors for the retinoid and rexinoid nuclear receptors. These pathways are associated with adverse cardiometabolic and cancer outcomes but have lacked effective inhibitors until Kayothera's intervention.

Specializing in biotechnology and health care, Kayothera has developed unique, orally-available small molecules that offer new solutions for managing conditions such as diabetes, obesity, and cancer. Their approach is clinically validated, positioning them as innovators in drug development.

The company recently secured a grant investment on July 19, 2023, from reputable investors including the Andy Hill Cancer Research Endowment (CARE) Fund and the National Institute of General Medical Science. As they continue to develop their novel drug options, Kayothera is well-positioned to attract further interest from the venture capital community.